ASCO 2022 Bladder Cancer

Viewing 1-20 of 35 articles

ASCO 2022: Preliminary Results of a Phase Ib/II Combination Study of RC48-ADC, a Novel Humanized Anti-HER2 Antibody-Drug Conjugate With Toripalimab, a Humanized IgG4 mAb Against PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2022: HER-2 Is New Again in Bladder Cancer - Discussion

ASCO 2022: Improving Outcomes Across the Stages in Bladder Cancer - Discussion

ASCO 2022: Long-Term Outcomes in EV-301: 24-Month Findings From the Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma

ASCO 2022: Perioperative Chemoimmunotherapy With Durvalumab for Operable Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single Arm Phase II Trial SAKK 06/17

ASCO 2022: RC48-ADC For Metastatic Urothelial Carcinoma With HER2-Positive: Combined Analysis of RC48-C005 and RC48-C009 Trials

ASCO 2022: A Phase II Study of RC48-ADC in HER2-Negative Patients With Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2022: Avelumab As the Basis of Neoadjuvant Regimen in Platinum-Eligible and -Ineligible Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: AURA (Oncodistinct-004) Trial

ASCO 2022: Long-Term Outcomes in Patients with Advanced Urothelial Carcinoma (UC) Who Received Avelumab First-Line Maintenance with or Without Second-Line Treatment: Exploratory Analyses from JAVELIN Bladder 100

ASCO 2022: Toripalimab (Anti-PD-1) Monotherapy as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma (POLARIS-03): Two-Year Survival Update and Biomarker Analysis

ASCO 2022: Defining “Platinum-Ineligible” Patients with Metastatic Urothelial Cancer (mUC)

ASCO 2022: Preliminary Results from Phase Ib/II Neoadjuvant CG0070 and Nivolumab (N) for Cisplatin (C)-Ineligible Muscle Invasive Bladder Cancer (MIBC)

ASCO 2022: Association of DNA Damage Response Gene Mutations and Response to Neoadjuvant Cisplatin-Based Chemotherapy in MIBC Patients Enrolled Onto SWOG S1314

ASCO 2022: Interim Results from a Multicenter Clinical Study of Tislelizumab Combined with Gemcitabine and Cisplatin as Neoadjuvant Therapy for Patients with cT2-T4aN0M0 MIBC

ASCO 2022: Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The U.S. Physician PARADIGM Study (Part 2)

ASCO 2022: Avelumab First-Line (1L) Maintenance for Advanced Urothelial Carcinoma (aUC): Long-Term Outcomes from JAVELIN Bladder 100 in Subgroups Defined by Response to 1L Chemotherapy

ASCO 2022: Efficacy of Hyperthermic-Intra-Vesical Chemotherapy in Patients with BCG-Refractory Nonmuscle-Invasive Bladder Cancer

ASCO 2022: A Randomised, Double Blind, Phase II Clinical Trial of Maintenance Cabozantinib Following Chemotherapy for Metastatic Urothelial Carcinoma: Final Analysis of the ATLANTIS Cabozantinib Comparison

ASCO 2022: Real-World Treatment Patterns and Clinical Outcomes with First-Line Therapy in Cisplatin-Eligible and Ineligible Patients with Advanced Urothelial Carcinoma

ASCO 2022: A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin, Unresponsive High-Risk, Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B

1
2